

**AMENDMENT**

A marked up version of the application showing the amendments is attached hereto as Exhibit A. Matter that has been deleted is indicated by brackets and matter that has been added is indicated by underlining. Please amend the application as follows:

**IN THE CLAIMS:**

Please amend claim 1 as follows:

C' 1. (Three Times Amended) A method for treating an autoimmune disease of the mouth comprising topically contacting the mouth of a patient in need of such treatment with a formulation consisting of a pharmaceutically acceptable carrier, an effective amount of a member selected from the group consisting of azathioprine, 6-mercaptopurine, 6-thioguanine nucleotide, a pharmaceutically acceptable salt of azathioprine, a pharmaceutically acceptable salt of 6-mercaptopurine, and a pharmaceutically acceptable salt of 6-thioguanine nucleotide, and optionally a non-steroidal anti-inflammatory agent.

**REMARKS**

Claims 1, 3-10, 12-19, 21-28 and 30-39 are pending in this application. Claim 1 has been amended, support for which is found at page 8, lines 12-14. Reconsideration of the application and allowance of claims 1, 3-10, 12-19, 21-28 and 30-39 is respectfully requested in view of the following remarks.

**A. Response to Objections**

**1. 37 C.F.R. § 1.75(c)**

**a. Objection to claims 37-39 as being of improper form**

At page 2 of Paper No. 13, claims 37-39 are objected to under 37 C.F.R. § 1.75(c) as being of improper form for failing to further limit the subject matter of a previous claim. The Examiner alleges that claims 37-39 improperly add a second pharmaceutical agent to the composition employed in the method of claim 1, which recites the close transitional phrase